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Introduction: We assessed the eﬀects of pilsicainide, a pure Naþ channel blocker, and
nifekalant, a pure rapid delayed rectiﬁer potassium current (IKr) blocker, on the electro-
physiological characteristics within the pulmonary vein (PV) and at the PV-left atrial (LA)
junction.
Methods and Results: We used a basket catheter for PV mapping in 38 patients with
paroxysmal atrial ﬁbrillation (AF). Programmed stimulation was performed in the distal PV
and PV-LA junction before and after the infusion of pilsicainide (1mg/kg; n ¼ 24) or
nifekalant (0.3mg/kg; n ¼ 14). Both drugs signiﬁcantly prolonged the eﬀective refractory
period (ERP) of the distal PV and PV-LA junction. Pilsicainide signiﬁcantly decreased the
ERP heterogeneity of the PV and PV-LA junction (36 43 vs. 9 60ms, P < 0:05). In
contrast, nifekalant signiﬁcantly increased the ERP heterogeneity of the PV and PV-LA
junction (from 38 34 to 60 46ms, P < 0:01). Pilsicainide signiﬁcantly prolonged the
conduction time (S1-A1) from the distal PV to the PV-LA junction (from 42 12 to
63 26ms, P < 0:001), whereas this did not change with nifekalant.
Conclusions: In AF patients, pilsicainide has antiarrhythmic eﬀects mainly on the distal PV
by modifying the ERP and conduction properties. In contrast, nifekalant has antiarrhythmic
eﬀects mainly on the PV-LA junction by modifying the ERP.
(J Arrhythmia 2010; 26: 259–266)
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Introduction
Atrial ﬁbrillation (AF) is one of the most common
arrhythmias seen clinically. Based on the guidelines
of the ACC/AHA, both Naþ channel blockers (class
I antiarrhythmic drugs) and Kþ channel blockers
(class III antiarrhythmic drugs) can be used to treat
AF. However, recent studies have mainly focused on
their eﬀects on atrial muscle. The mechanism of
arrhythmogenicity in the pulmonary vein (PV) has
been explained in previous reports.1,2) Furthermore,
some reports have suggested that the atrial myocar-
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dium in the PV sleeves is important for the initiation
and maintenance of AF.5,20,21) In fact in patients with
paroxysmal AF, there is a high likelihood that the AF
can be cured with PV isolation.1–4) Kumagai et al.
demonstrated the eﬀect of a Naþ channel blocker,
pilsicainide, on the PV.6) However, the eﬀects of
these antiarrhythmic drugs on the PV are not well
known. A multielectrode basket catheter can be a
very useful tool for detailed PV mapping and
isolation.7) Therefore, in this study we evaluated
the electrophysiologic eﬀects of pilsicainide, a pure
Naþ channel blocker (class Ic drug), and nifekalant,
a pure rapid delayed rectiﬁer potassium current (IKr)
blocker (class III drug), on the PV in AF patients.
Methods
Patient characteristics
The patients were divided into two groups: a
pilsicainide group and a nifekalant group. The
pilsicainide group consisted of 24 patients (20
men) with a mean age of 59 8 years, and the
nifekalant group consisted of 14 patients (12 men)
aged 54 12 (n.s.) with paroxysmal AF who under-
went an electrophysiological study. None of the
patients had previously undergone PV isolation.
There were no signiﬁcant diﬀerences between the
two groups with regard to AF history, hypertension,
diabetes mellitus, mitral regurgitation, coronary
artery disease, cardiomyopathy, left atrial dimension,
ejection fraction or PV diameter (Table 1). All
antiarrhythmic drugs were discontinued for the
duration of at least ﬁve drug-serum half-lives before
the study. Informed consent was obtained from all
patients before the study.
Catheter positions
Three multipolar electrode catheters (Daig Corp.,
USA) were positioned in the right atrial appendage
(RAA), the His bundle area (His), and the distal
coronary sinus (CS), respectively, and a 31-mm, 64-
pole basket catheter (EP Technologies, USA) was
placed in the left superior PV. All catheters
positioned in the left atrium (LA) were inserted by
septal puncture. Next, the basket catheter was placed
in the PV, and the proximal basket catheter elec-
trodes (electrodes 7, 8) were then placed in the PV-
LA junction by PV angiography performed with an
angiocatheter (6-French, Baxter, USA) or a long
sheath (SL-1, Daig Corp., USA) (Figure 1). Later, an
electrode catheter for the His was introduced into
the left atrial appendage (LAA) through the same
transseptal puncture site. Intravenous heparin was
administered in a single bolus of 5000 IU and then at
1,000 IU per hour (continuous venous infusion) after
the atrial transseptal procedure.
Electrophysiological study and stimulation proto-
col
Control study
During sinus rhythm, the eﬀective refractory
periods (ERPs) were measured at the RAA and
Table 1 Comparison of Parameters Between Pilsicainide
and Nifekalant Groups
Pilsicainide
(n ¼ 24)
Nifekalant
(n ¼ 14) P
Age 59 8 54 12 n.s.
Male/Female 20/4 12/2 n.s.
AF history (years) 3 2 3 4 n.s.
Hypertension 1(4%) 1(7%) n.s.
Diabetes mellitus 2(8%) 0(0%) n.s.
MR 10(42%) 3(21%) n.s.
CAD 3(13%) 1(7%) n.s.
CM 1(4%) 2(14%) n.s.
LAd (mm) 38 5 39 6 n.s.
EF(%) 64 10 64 9 n.s.
PV diameter 19 3 19 5 n.s.
MR: mitral regurgitation, CAD: coronary artery diseases,
CM: cardiomyopachy, LAd: left atrial dimension, EF:
ejection fraction, PV: pulmonary vein
RAA
LAA
CS
LSPV
Ab (RSPV)
12346 58 7
PV-LA junction
A B
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D
EF
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Figure 1 Basket catheter-guided pulmonary vein (PV)
mapping.
A basket catheter was positioned in the PV. Distal pacing was
performed from the distal electrode pair (bipoles 1, 2) and PV-left
atrium (LA) junctional pacing was implemented at the proximal
pacing pair (bipoles 9, 10). The proximal electrode (bipoles 7, 8)
was located at the PV-LA junction.
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LAA and at the intra-PV and LA-PV junction. The
ERPs of the RAA and LAA were measured using a
multipolar electrode catheter, and intra-PV mapping
was performed with a basket catheter. PV mapping
consisted of measurement of the conduction time of
intra-PV and the ERP of the distal PV and PV-LA
junction and ERP heterogeneity. We deﬁned ERP
heterogeneity as the diﬀerence between PV-LA
junction and PV distal ERPs within the same PV.
Intra-PV pacing was performed from the distal
(electrodes 1, 2) and proximal (electrodes 7, 8)
electrode pairs of all splines of the basket catheter. It
was also used to pace 2 or 3 diﬀerent sites within the
PV and PV-LA junction, including the bilateral,
inferior, superior and posterior walls. The conduc-
tion time from the distal PV to the PV-LA junction
was measured from the pacing artifact to the atrial
potentials recorded during the drive cycle. The
stimulus strength was determined at twice the
diastolic threshold by a programmed stimulator
(SEC-3102, Nihon Kohden, Japan). Bipolar intra-
cardiac electrograms were recorded at a ﬁlter setting
of 30 to 500Hz and stored digitally on a polygraph
(Labosystem DUO, Bard, USA) simultaneously with
the surface ECG. Stable pacing sites were deter-
mined only if the threshold was <5V. After a basic
drive cycle of 8 stimuli at 600ms, an extrastimulus
coupled at 400ms was applied and automatically
decremented in 10ms steps. We conﬁrmed the
reproducibility of the measurement, especially in
the distal PV. When AF was induced by the
extrastimulus, we terminated AF by DC shock and
repeated the measurement. The ERP was deﬁned as
the longest coupling interval at which a premature
stimulus failed to capture local muscle (Figure 2).
Drug study
After the control study, the pilsicainide group was
given a loading dose of 1mg/kg of pilsicainide over
5 minutes, and the nifekalant group was given a
loading dose of 0.3mg/kg of nifekalant over 5
minutes. After drug administration, the parameters
A 7-8
B 7-8
C 7-8
D 7-8
E 7-8
G 7-8
H 7-8
A B
II
S1 S2
F 7-8
S1 S2
A 7-8
B 7-8
C 7-8
D 7-8
E 7-8
G 7-8
H 7-8
II
F 7-8
100 250
60 242
102 146
Figure 2
Programmed stimulation was performed from the distal PV using a basket catheter. All proximal (bipoles 7, 8) electrograms with the
basket catheter spline in the left superior PV are shown. A: Before pilsicainide. The maximum drive cycle conduction time (S1-A1) was
60msec. Atrial ﬁbrillation (AF) was induced when an extrastimulus (S2) is decremented to 100msec. ERP of the distal PV is 100msec. B:
After pilsicainide. Maximum S1-A1 was prolonged to 102msec. When S2 was decremented to 250msec, AF was not induced. ERP of the
distal PV was prolonged to 240msec.
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were measured repeatedly. If AF was not terminated
within 5 minutes of drug infusion, AF was termi-
nated by DC shock, and the measurements were
repeated after 10 minutes. All measurements were
ﬁnished within 40 minutes after the completion of
drug infusion.
Statistical analysis
Continuous variables are expressed as mean
SD. Paired or unpaired values were compared by
Student’s t-test, the Mann-Whitney U test or the chi-
square test, as appropriate. p < 0:05 was considered
statistically signiﬁcant.
Results
Pilsicainide group
There were no signiﬁcant diﬀerences in ERP
before loading between the pilsicainide and nifeka-
lant groups (distal PV: 189 51 vs 189 37, n.s.,
PV-LA junction: 217 42 vs 220 46, n.s.).
Pilsicainide prolonged distal PV ERPs from
189 51ms to 209 55ms (p < 0:002) and PV-
LA junction ERPs from 217 42ms to 227 60ms
(p < 0:03). ERPs of distal PVs were shorter than
those of the PV-LA junction (189 51ms vs
217 42ms). Therefore, pilsicainide signiﬁcantly
decreased the ERP heterogeneity of the PV and PV-
LA junction, deﬁned as the diﬀerence between the
PV-LA junction and PV distal ERPs within the same
PV (36 43ms vs. 9 60ms, p < 0:05). Pilsicai-
nide signiﬁcantly prolonged the maximum conduc-
tion time during the drive cycle from the distal PV to
the PV-LA junction (Maximum S1-A1, 42 12ms
to 63 26ms, p < 0:001). Pilsicainide signiﬁcantly
prolonged RAA and LAA ERPs (RAA: from
232 22ms to 246 24ms, p < 0:02, LAA: from
234 27ms to 249 24ms, p < 0:01) (Table 2).
In three cases, after the injection of pilsicainide,
electrograms in the PV gradually disappeared from
the PV-LA junction side, which suggested pharma-
cological LA-PV conduction block during AF
(Figure 3).
Nifekalant group
As noted above, there were no signiﬁcant dif-
ferences in the ERP at baseline between the
pilsicainide and nifekalant groups (distal PV:
189 51ms vs 189 37ms, n.s., PV-LA junction:
217 42ms vs 220 46ms, n.s.). Nifekalant
prolonged PV distal ERPs from 189 37ms to
197 53ms (p < 0:05) and PV-LA junction ERPs
from 220 46ms to 253 55ms (p < 0:001).
Therefore, nifekalant signiﬁcantly increased the
ERP heterogeneity of the PV and PV-LA junction
(from 38 34ms to 60 46ms, p < 0:01). No
signiﬁcant change in the maximum conduction time
during the drive cycle from the distal PV to the PV-
LA junction was seen in the nifekalant group (from
S1-A1, 38 12ms to 43 17ms, n.s.). Nifekalant
signiﬁcantly prolonged RAA and LAA ERPs (RAA:
from 236 26ms to 279 53ms, p < 0:01; LAA:
239 34ms to 277 47ms, p < 0:02 (Table 2). In
Table 2 Comparison of Parameters Between Pilsicainide and Nifekalant Groups
Pilsicainide (n ¼ 24) Nifekalant (n ¼ 14)
pre-i.v. post-i.v. P pre-i.v. post-i.v. P
ERP (msec)
distal PV 189 51 209 55 <0.002 189 37 197 53 <0.05
PV-LA junction 217 42 227 60 <0.03 220 46 253 55 <0.001
RAA 232 22 246 24 <0.02 236 26 279 53 <0.01
LAA 234 27 249 24 <0.01 239 34 277 47 <0.02
heterogeneity 36 43 9 60 <0.05 38 34 60 46 <0.002
Conduction (Max S1-A1) (msec)
distal to proxymal 42 12 63 26 <0.001 38 12 43 17 n.s.
proxymal to distal 42 7 55 13 <0.005 41 15 42 14 n.s.
Induced AF (%)
distal PV 10 6.7 n.s. 4.0 38.5 <0.002
PV-LA junction 3.8 11.5 n.s. 9.5 14.3 n.s.
ERP: eﬀective refractory period, PV: pulmonary vein, LA: left atrium, right atrial appendage, LAA: left atrial appendage
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two cases, after the injection of nifekalant, electro-
grams in the LA were gradually organized, except
for intra PV electrograms (Figure 4).
Discussion
Our main ﬁndings are as follows. First, pilsicai-
nide increased ERP in PV, decreased the ERP
heterogeneity of the PV and PV-LA junction, and
prolonged the conduction time within the PV.
Second, nifekalant increased PV-LA junction ERP
and signiﬁcantly increased the ERP heterogeneity
of the PV and PV-LA junction. Nifekalant did not
aﬀect conduction properties within the PV.
Electrophysiological effects of pilsicainide on the
PV-LA junction and distal PV
Pilsicainide, a class Ic antiarrhythmic drug, was
originally developed in Japan. It has pure Naþ
channel-blocking action with slow recovery kinet-
ics.8) At high concentrations, it shows minimal-to-
moderate inhibition of ionic currents passing through
Ca2þ and Kþ channels, although this eﬀect should be
negligible at a plasma concentration that is eﬀective
for the treatment of arrhythmias.9,10) Some previous
studies using wavelength theory have explained the
inducibility and stability of AF.11,12) Class I and III
antiarrhythmic drugs have antiﬁbrillatory eﬀects on
AF, as shown using wavelength theory in a previous
study.13) Other reports have demonstrated that
pilsicainide decreased intra-atrial conduction veloc-
ity and signiﬁcantly increased atrial ERP and the
wavelength.14–16) A few clinical reports have found
that this drug is eﬀective for terminating paroxysmal
and persistent AF.17–19) However, Wijﬀels et al.13)
reported that pharmacologic cardioversion of AF
cannot be explained by the prolongation of wave-
length. Jais et al.20) demonstrated that patients with
AF had distinctive electrophysiological properties
for arrhythmogenicity. Recently, reentry formation
has been demonstrated at the PV-LA junction, and
PV distal ERP was shorter than PV-LA junction
before-i.v.
partial pharmacologic
isolation, post i.v.
pharmacologic 
isolation, post i.v.
A
B
C
D
E
F
G
H
HRA
LA
CS
Figure 3 Changes in PV electrograms by pilsicainide.
The PV potential was observed in all of the electrodes before pilsicainide injection (left). In the A spline, the distal PV from LA
conduction is observed, and the H spline shows similar results. After the injection of pilsicainide, incomplete pharmacologic PV isolation
occurred (middle electrogram). The mean AF cycle length was prolonged and PV-LA conduction was blocked from the LA to the PV at
the A and H splines by pilsicainide. While distal PV potential disappeared from the B to E splines, that in the neighborhood of the PV-LA
junction potential remained. Pharmacologic PV-LA isolation was complete just after all PV potential suddenly disappeared during AF by
pilsicainide (right).
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ERP, while the conduction delay was longer than
that at the PV-LA junction.4,20–22) In this study,
similar results were seen with programmed stimula-
tion. Thus, the diﬀerence between the characteristics
of the distal PV and the PV-LA junction may play a
very important role in both the onset and main-
tenance of AF. However, previous studies were
unclear regarding the eﬀects of antiarrhythmic drugs
on the atrium and the PV and PV-LA junction. In
this study, we noted that pilsicainide signiﬁcantly
increased the ERPs of both the distal PV and the PV-
LA junction and prolonged the conduction delay
within the PV (a greater delay was seen in the distal
PV than that in the PV-LA junction). The hetero-
geneity in ERPs between the distal PV and PV-LA
junction suggests arrhythmogenicity. In this study,
we observed a decrease in ERP heterogeneity of
the PV and PV-LA junction after the injection of
pilsicainide. These ﬁndings may suggest an antiar-
rhythmic eﬀect through the enhancement of an
arrhythmic substrate. Thus, pilsicainide aﬀected AF
not only in the atria but also in the PV and PV-LA
junction. Pharmacological PV isolation was achiev-
ed by prolonging conduction at the PV-LA junction,
and AF was immediately terminated (Figure 3).
Therefore, conduction delay by pilsicainide might
terminate AF caused by reentry formation within
PVs or the PV-LA junction. In addition, ERP
prolongation by pilsicainide might prevent AF
caused by PV foci. These eﬀects of pilsicainide on
the PV-LA junction and distal PV might explain one
of the important mechanisms in the prevention and
termination of AF by this class Ic drug.
Electrophysiological effects of nifekalant on the
PV-LA junction and distal PV
Nifekalant, a class III antiarrhythmic drug, was
also originally developed in Japan. It is a compara-
tively pure I Kr-channel blocker.23) However, nife-
kalant also has a weak inhibitory eﬀects on the
adenosine triphosphate-sensitive potassium channel
current (IK.ATP) and Na
þ-activated potassium chan-
nel current (IK.Na).
24,25) Watanabe et al. demonstrated
that nifekalant prolonged ERP and the duration of
the monophasic action potential in the human
ventricle, but did not aﬀect the intra-atrial conduc-
CS
A
B
C
D
E
F
G
H
before-i.v.
HRA
LA
pharmacologic PV-LA discrepancy
Figure 4 Changesin PV electrograms by nifekalant.
The PV and left atrial potentials show irregular electrograms before the injection of nifekalant (left). However, while the atrial potential
changed to a comparatively regular potential, PV electrogramswere were not aﬀected by the injection of nifekalant during AF. Thus, a PV-
to-LA discrepancy was observed (right).
J Arrhythmia Vol 26 No 4 2010
264
tion time.26) Several atrial studies have found that
nifekalant increased the atrial eﬀective refractory
period (AERP) and the wavelength for atrial reentry,
and terminated arrhythmia, and may be eﬀective for
preventing AF due to prolongation of the AERP.27,28)
In this study, we observed that nifekalant increased
the ERP of the PV-LA junction more than that of the
distal PV and did not signiﬁcantly change the intra-
PV conduction time. Thus, the eﬀect of nifekalant
mainly involves prolongation of the ERP of atrial
muscle including the PV-LA junction compared to
the distal PV without changing the conduction time.
The inhibition of distal PV foci by an increase in PV
ERP may be weaker than that in the PV-LA junction
in comparison with the eﬀects of pilsicainide, since
the prolongation of ERP in distal PV by nifekalant
was weaker than that in the PV-LA junction. In
addition, as a unique eﬀect of nifekalant, we noted a
PV-to-LA discrepancy just before AF termination
(Figure 4). This phenomenon was completely oppo-
site that in the case of pilsicainide, and may be due
to shortening of the action potential duration and
refractoriness and suppressing automaticity in the
PV by nifekalant.29) In this study, ERP heterogeneity
of the PV and PV-LA junction after the injection of
nifekalant was signiﬁcantly increased. AF may have
been terminated due to the eﬀect of prolonged ERP
of atrial muscle including the PV-LA junction and
the prevention of PV-LA junction and/or non-PV
foci. The eﬀect of nifekalant on atrial muscle
including the PV-LA junction and distal PV might
explain one of the important mechanisms in the
prevention and termination of AF by this class III
drug.
Limitations of the study
There are several limitations in our study. First,
pharmacologic isolation and PV-to-LA dissociation
were not always observed. Second, we measured
these parameters with only one PV and did not
simultaneously observe the eﬀects on other PVs.
Thus, the eﬀects of pilsicainide and nifekalant on
other PVs are unclear. Third, pilsicainide is associ-
ated with use-dependent block,8) and nifekalant is
characterized by its use-dependent block of INa.
Nifekalant is also characterized by its reverse use-
dependent prolongation of action potential dura-
tions.30) However, we used a BCL of only 600msec
when measuring ERP and conduction time. There-
fore, diﬀerent results may be obtained when diﬀerent
short cycle lengths are used. Last, we only measured
the conduction time of PV, and thus the eﬀect on the
conduction time in the atrium is still unknown.
Conclusion
In conclusion, these results demonstrate that a
Naþ channel blocker and a Kþ channel blocker have
diﬀerent antiarrhythmic eﬀects at the PV and PV-LA
junction. Conduction delay by pilsicainide might
terminate AF caused by reentry formation within
PVs or the PV-LA junction, and the prolongation of
ERP by pilsicainide might prevent AF caused by PV
foci. In contrast, the main antiarrhythmic eﬀect of
nifekalant may be the termination of AF due to
prolongation of the ERP of atrial muscle including
the PV-LA junction and the prevention of AF
through acting on the PV-LA junction and/or non-
PV foci. The mechanism for the diﬀerence in the
eﬀects of these drugs on PV and PV-LA junction is
not clear. However, these ﬁndings may be important
for understanding the antiarrhythmic eﬀects of Naþ
channel blockers and Kþ channel blockers on AF.
Acknowledgment
We thank Hiroo Noguchi, M.D., Hideo Takashima, M.D.,
Soichi Muraoka, M.D., and Chiharu Mitsutake, M.D., for their
technical assistance.
References
1) Haissaguerre M, Jais P, Shah DC, et al: Spontaneous
initiation of atrial ﬁbrillation by ectopic beats originating
in the pulmonary veins. N Engl J Med 1998; 339: 659–
666
2) Chen SA, Hsieh MH, Tai CT, et al: Initiation of atrial
ﬁbrillation by ectopic beats originating from the pulmo-
nary veins: electrophysiological characteristics, pharma-
cological responses, and eﬀects of radiofrequency
ablation. Circulation 1999; 100: 1879–1886
3) Pappone C, Rosanio S, Oreto G, et al: Circumferential
radiofrequency ablation of pulmonary vein ostia: A new
anatomic approach for curing atrial ﬁbrillation. Circu-
lation 2000; 102: 2619–2628
4) Oral H, Knight BP, Ozaydin M, et al: Segmental ostial
ablation to isolate the pulmonary veins during atrial
ﬁbrillation: feasibility and mechanistic insights. Circu-
lation 2002; 106: 1256–1262
5) Kumagai K, Yasuda T, Tojo H, et al: Role of rapid
focal activation in the maintenance of atrial ﬁbrillation
originating from the pulmonary veins. Pacing Clin
Electrophysiol 2000; 23: 1823–1827
6) Kumagai K, Tojo H, Noguchi H, et al: Eﬀects of the
NAþ channel blocker pilsicainide on the electrophysio-
logic properties of pulmonary veins in patients with atrial
ﬁbrillation. J Cardiovasc Electrophysiol 2004; 15: 1396–
1401
7) Kumagai K, Noguchi H, Ogawa M, et al: New approach
to pulmonary vein isolation for atrial ﬁbrillation using a
multielectrode basket catheter. Circ J 2006; 70(1): 88–93
8) Kanki H, Mitamura H, Takatsuki S, et al: Postrepolari-
zation refractoriness as a potential anti-atrial ﬁbrillation
mechanism of pilsicainide, a pure sodium channel
Yasuda T Comparison of Naþ and Kþ Channel Blockers in PVs
265
blocker with slow recovery kinetics. Cardiovasc Drugs
Ther 1998; 12: 475–482
9) Kodama I, Ogawa S, Inoue H, et al: Proﬁles of aprindine,
cibenzoline, pilsicainide and pirmenol in the framework
of the Sicilian Gambit. The Guideline Committee for
Clinical Use of Antiarrhythmic Drugs in Japan (Working
Group of Arrhythmias of the Japanese Society of
Electrocardiology). Jpn Circ J 1999; 63: 1–12
10) Yamashita T, Murakawa Y, Sezaki K, et al: Uniqueness
of pilsicainide in class Ic antiarrhythmics. Jpn Heart J
1998; 39: 389–397
11) Rensma PL, Allessie MA, Lammers WJ, et al: Length of
excitation wave and susceptibility to reentrant atrial
arrhythmias in normal conscious dogs. Circ Res 1988;
62: 395–410
12) Kawase A, Ikeda T, Nakazawa K, et al: Widening of the
excitable gap and enlargement of the core of reentry
during atrial ﬁbrillation with a pure sodium channel
blocker in canine atria. Circulation 2003; 107: 905–910
13) Wijﬀels MC, Dorland R, Mast F, et al: Widening of the
excitable gap during pharmacological cardioversion of
atrial ﬁbrillation in the goat: eﬀects of cibenzoline,
hydroquinidine, ﬂecainide, and d-sotalol. Circulation
2000; 102: 260–267
14) Sakai R, Inoue D, Ishibashi K, et al: Kinetics of
frequency-dependent conduction delay by class I anti-
arrhythmic drugs in human atrium. J Cardiovasc Phar-
macol 1995; 25: 953–960
15) Iwasa A, Okumura K, Tabuchi T, et al: Eﬀects of
pilsicainide and propafenone on vagally induced atrial
ﬁbrillation: role of suppressant eﬀect in conductivity.
Eur J Pharmacol 1998; 356: 31–40
16) Shinagawa K, Mitamura H, Takeshita A, et al: Determi-
nation of refractory periods and conduction velocity
during atrial ﬁbrillation using atrial capture in dogs:
direct assessment of the wavelength and its modulation
by a sodium channel blocker, pilsicainide. J Am Coll
Cardiol 2000; 35: 246–253
17) Atarashi H, Inoue H, Hiejima K, et al: Conversion of
recent-onset atrial ﬁbrillation by a single oral dose of
Pilsicainide (Pilsicainide Suppression Trial on Atrial
Fibrillation). The PSTAF Investigators. Am J Cardiol
1996; 78: 694–697
18) Okishige K, Fukunami M, Kumagai K, et al: Pharmaco-
logical conversion of persistent atrial ﬁbrillation into
sinus rhythm with oral pilsicainide: pilsicainide suppres-
sion trial for persistent atrial ﬁbrillation II. Circ J 2006;
70(6): 657–661
19) Kumagai K, Abe H, Hiraki T, et al: Single oral
administration of pilsicainide versus infusion of disopyr-
amide for termination of paroxysmal atrial ﬁbrillation: a
multicenter trial. Pacing Clin Electrophysiol 2000; 23:
1880–1882
20) Jais P, Hocini M, Macle L, et al: Distinctive electro-
physiological properties of pulmonary veins in patients
with atrial ﬁbrillation. Circulation 2002; 106: 2479–2485
21) Arora R, Verheule S, Scott L, et al: Arrhythmogenic
substrate of the pulmonary veins assessed by high-
resolution optical mapping. Circulation 2003; 107:
1816–1821
22) Kumagai K, Ogawa M, Noguchi H, et al: Electro-
physiologic properties of pulmonary veins assessed using
a multielectrode basket catheter. J Am Coll Cardiol
2004; 43: 2281–2289
23) Nakaya H, Uemura H: Electropharmacology of nifeka-
lant, a new class III antiarrhythmic drug. Cardiovasc
Drug Rev 1998; 16: 133–144
24) Martin DK, Nakaya Y, Wyse KR, et al: Inhibition of
ATP-sensitive potassium channels in cardiac myocytes
by the novel class III antiarrhythmic agent MS 551.
Pharmacol Toxicol 1995; 77: 65–70
25) Mori K, Saito T, Masuda Y, Nakaya H: Eﬀects of class
III antiarrhythmic drugs on the Na(+)-activated K+
channels in guinea-pig ventricular cells. Br J Pharmacol
1996; 119: 133–141
26) Watanabe H, Watanabe I, Nakai T, et al: Frequency-
dependent electrophysiological eﬀects of ﬂecainide,
nifekalant and d,l-sotalol on the human atrium. Jpn Circ
J 2001; 65: 1–6
27) Minami T, Isomoto S, Nakao K, et al: Eﬀects of
intravenous nifekalant, a class III antiarrhythmic drug, on
atrial vulnerability parameters in patients with parox-
ysmal atrial ﬁbrillation. Pacing Clin Electrophysiol 2004;
27: 212–217
28) Wang J, Bourne GW, Wang Z, et al: Comparative
mechanisms of antiarrhythmic drug action in experi-
mental atrial ﬁbrillation. Importance of use-dependent
eﬀects on refractoriness. Circulation 1993; 88: 1030–
1044
29) Verheijck EE, van Ginneken AC, Bourier J, et al: Eﬀects
of delayed rectiﬁer current blockade by E-4031 on
impulse generation in single sinoatrial nodal myocytes of
the rabbit. Circ Res 1995 Apr; 76(4): 607–615
30) Wang J, Feng J, Nattel S: Class III antiarrhythmic drug
action in experimental atrial ﬁbrillation. Diﬀerences in
reverse use dependence and eﬀectiveness between d-
sotalol and the new antiarrhythmic drug ambasilide.
Circulation 1994; 90: 2032–2040
J Arrhythmia Vol 26 No 4 2010
266
